Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 61

1.

Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.

Pelletier EM, Pawaskar M, Smith PJ, Best JH, Chapman RH.

J Med Econ. 2012;15(6):1039-50. doi: 10.3111/13696998.2012.688903. Epub 2012 May 24.

PMID:
22533526
2.

Determining initial and follow-up costs of cardiovascular events in a US managed care population.

Chapman RH, Liu LZ, Girase PG, Straka RJ.

BMC Cardiovasc Disord. 2011 Mar 16;11:11. doi: 10.1186/1471-2261-11-11.

3.

The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications.

Chapman RH, Kowal SL, Cherry SB, Ferrufino CP, Roberts CS, Chen L.

Value Health. 2010 Sep-Oct;13(6):685-94. doi: 10.1111/j.1524-4733.2010.00774.x. Review.

PMID:
20825627
4.
5.

Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.

Hussein MA, Chapman RH, Benner JS, Tang SS, Solomon HA, Joyce A, Foody JM.

Am J Cardiovasc Drugs. 2010;10(3):193-202. doi: 10.2165/11530680-000000000-00000.

PMID:
20387911
6.

The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs*.

Chapman RH, Ferrufino CP, Kowal SL, Classi P, Roberts CS.

Int J Clin Pract. 2010 Jan;64(2):169-81. doi: 10.1111/j.1742-1241.2009.02196.x. Review.

PMID:
20089007
7.

Can adherence to antihypertensive therapy be used to promote adherence to statin therapy?

Chapman RH, Pelletier EM, Smith PJ, Roberts CS.

Patient Prefer Adherence. 2009 Nov 3;3:265-75.

8.

Are high-risk hypertensive patients being prescribed concomitant statin therapy?: a retrospective cohort study.

Chapman RH, Petrilla AA, Berman L, Benner JS, Tang SS.

Am J Cardiovasc Drugs. 2009;9(5):299-308. doi: 10.2165/11312110-000000000-00000.

PMID:
19791839
9.

Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting.

Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH.

Cardiovasc Diabetol. 2009 Sep 26;8:53. doi: 10.1186/1475-2840-8-53.

10.

Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy.

Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, Schwartz JS.

Am J Health Syst Pharm. 2009 Aug 15;66(16):1471-7. doi: 10.2146/ajhp080238.

PMID:
19667004
11.

Drug titration patterns and HbA 1c levels in type 2 diabetes.

Maclean JR, Chapman RH, Ferrufino CP, Krishnarajah G.

Int J Clin Pract. 2009 Jul;63(7):1008-16. doi: 10.1111/j.1742-1241.2009.02094.x.

12.

Generic and therapeutic statin switches and disruptions in therapy.

Chapman RH, Benner JS, Girase P, Benigno M, Axelsen K, Liu LZ, Nichol MB.

Curr Med Res Opin. 2009 May;25(5):1247-60. doi: 10.1185/03007990902876271 .

PMID:
19344292
13.

Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study.

Chapman RH, Petrilla AA, Benner JS, Schwartz JS, Tang SS.

Drugs Aging. 2008;25(10):885-92.

PMID:
18808213
14.

Comparison of self-reported survey (SHIELD) versus NHANES data in estimating prevalence of dyslipidemia.

Bays HE, Chapman RH, Fox KM, Grandy S; SHIELD Study Group.

Curr Med Res Opin. 2008 Apr;24(4):1179-86. doi: 10.1185/030079908X280527 . Epub 2008 Mar 14.

PMID:
18346311
16.
17.

The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys.

Bays HE, Chapman RH, Grandy S; SHIELD Investigators' Group.

Int J Clin Pract. 2007 May;61(5):737-47. Erratum in: Int J Clin Pract. 2007 Oct;61(10):1777-8.

18.

Can we better prioritize resources for cost-utility research?

Neumann PJ, Rosen AB, Greenberg D, Olchanski NV, Pande R, Chapman RH, Stone PW, Ondategui-Parra S, Nadai J, Siegel JE, Weinstein MC.

Med Decis Making. 2005 Jul-Aug;25(4):429-36.

PMID:
16061895
19.

Predictors of adherence with antihypertensive and lipid-lowering therapy.

Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, Schwartz JS.

Arch Intern Med. 2005 May 23;165(10):1147-52.

PMID:
15911728
20.

When does quality-adjusting life-years matter in cost-effectiveness analysis?

Chapman RH, Berger M, Weinstein MC, Weeks JC, Goldie S, Neumann PJ.

Health Econ. 2004 May;13(5):429-36. Review.

PMID:
15127423
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk